Acer Therapeutics (NASDAQ:ACER) issued its earnings results on Friday. The biopharmaceutical company reported ($0.43) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.53) by $0.10, MarketWatch Earnings reports.

ACER stock traded up $0.29 during midday trading on Friday, hitting $24.91. The company had a trading volume of 7,116 shares, compared to its average volume of 29,773. Acer Therapeutics has a 52 week low of $11.36 and a 52 week high of $34.10. The company has a market capitalization of $242.20 million, a P/E ratio of -6.49 and a beta of 2.75.

Several analysts have issued reports on the company. HC Wainwright set a $55.00 target price on Acer Therapeutics and gave the stock a “buy” rating in a research note on Monday, October 29th. BidaskClub downgraded Acer Therapeutics from a “hold” rating to a “sell” rating in a research report on Friday, October 19th. Raymond James upgraded Acer Therapeutics from an “outperform” rating to a “strong-buy” rating and boosted their price objective for the company from $31.00 to $46.00 in a research report on Friday, August 17th. Zacks Investment Research downgraded Acer Therapeutics from a “buy” rating to a “hold” rating in a research report on Thursday, August 16th. Finally, William Blair reiterated an “outperform” rating on shares of Acer Therapeutics in a research report on Tuesday, August 14th. One analyst has rated the stock with a sell rating, one has issued a hold rating, three have assigned a buy rating and two have issued a strong buy rating to the company’s stock. Acer Therapeutics currently has a consensus rating of “Buy” and an average target price of $48.00.

COPYRIGHT VIOLATION WARNING: This news story was originally reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this news story on another site, it was copied illegally and reposted in violation of United States and international trademark and copyright laws. The correct version of this news story can be viewed at https://www.thecerbatgem.com/2018/11/10/acer-therapeutics-acer-announces-quarterly-earnings-results.html.

Acer Therapeutics Company Profile

Acer Therapeutics Inc, a pharmaceutical company, develops therapies for the treatment of rare diseases with critical unmet medical needs. Its product candidates include Celiprolol for the treatment of vascular Ehlers-Danlos syndrome; and ACER-001 for the treatment of urea cycle disorders and maple syrup urine disease.

Featured Article: What factors cause inflation to rise?

Earnings History for Acer Therapeutics (NASDAQ:ACER)

Receive News & Ratings for Acer Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acer Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.